Although the prevalence of Bordetella parapertussis varies dramatically among studies in different populations with different vaccination regimens, there is broad agreement that whooping cough vaccines, composed only of B. pertussis antigens, provide little if any protection against B. parapertussis. In C57BL/6 mice, a B. pertussis whole-cell vaccine (wP) provided modest protection against B. parapertussis, which was dependent on IFN-γ. The wP was much more protective against an isogenic B. parapertussis strain lacking O-antigen than its wild-type counterpart. O-antigen inhibited binding of wP–induced antibodies to B. parapertussis, as well as antibody-mediated opsonophagocytosis in vitro and clearance in vivo. aP–induced antibodies also bound better in vitro to the O-antigen mutant than to wild-type B. parapertussis, but aP failed to confer protection against wild-type or O antigen–deficient B. parapertussis in mice. Interestingly, B. parapertussis–specific antibodies provided in addition to either wP or aP were sufficient to very rapidly reduce B. parapertussis numbers in mouse lungs. This study identifies a mechanism by which one pathogen escapes immunity induced by vaccination against a closely related pathogen and may explain why B. parapertussis prevalence varies substantially between populations with different vaccination strategies.
Citation: Zhang X, Rodríguez ME, Harvill ET (2009) O Antigen Allows B. parapertussis to Evade B. pertussis Vaccine–Induced Immunity by Blocking Binding and Functions of Cross-Reactive Antibodies. PLoS ONE 4(9): e6989. https://doi.org/10.1371/journal.pone.0006989
Editor: Ulrich A. Maus, Hannover School of Medicine, Germany
Received: June 11, 2009; Accepted: August 19, 2009; Published: September 14, 2009
Copyright: © 2009 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grant GM083113 (ETH) and ANPCyT PICT559 (MER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Whooping cough is an acute, highly contagious, paroxysmal coughing illness . The first whooping cough vaccines consisting of whole inactivated B. pertussis were licensed in the mid-1940s and led to a dramatic decrease of disease incidence , . However, the potential health risk associated with whole cell vaccines led to the development of acellular vaccines, consisting of some combination of B. pertussis antigens including pertussis toxin (PT), pertactin, filamentous hemaglutinin (FHA) and 2 fimbriae serotypes. Despite maintenance of high vaccine coverage, the reported whooping cough incidence has been increasing over the past 20 years in some developed countries , , although a large portion of whooping cough infections are thought to remain unreported . Both B. pertussis and B. parapertussis are causative agents of whooping cough ,  that appear to have evolved independently from distinct lineages of B. bronchiseptica through rearrangements and large scale gene loss, with B. parapertussis emerging more recently than B. pertussis , . Although they are closely related, a few striking differences exist between the human-adapted bordetellae. For example, B. parapertussis lipopolysaccharide (LPS) includes a repetitive membrane-distal O-antigenic structure, while B. pertussis only expresses lipid A and a branched-chain core oligosaccharide with a complex trisaccharide modification, but lacks O-antigen , . B. pertussis expresses PT, but B. parapertussis does not due to mutations in the promoter region , . Since differential diagnosis of B. pertussis and B. parapertussis does not affect the course of treatment, it is rarely performed in clinical settings , . The CDC does not list B. parapertussis as reportable , but a few epidemiological studies have reported the percentage of whooping cough cases caused by B. parapertussis to be from 1% to 98%, most commonly 4–40% . Although B. parapertussis appears to contribute substantially to disease, whooping cough vaccines are solely derived from B. pertussis .
Clinical and experimental data indicate that whooping cough vaccines are very efficacious against B. pertussis but not against B. parapertussis –, however, a mechanistic understanding of this phenomenon has not been described. While whooping cough vaccines may fail to generate efficient cross-immunity against B. parapertussis, it is also possible that cross-reacting adaptive immunity is generated but is evaded by B. parapertussis. Recently, our lab showed that the O-antigen of B. parapertussis shields it from B. pertussis-infection-induced antibodies , relevant to the natural immune-mediated competition between B. pertussis and B. parapertussis in unvaccinated population. However, nearly all people in industrialized countries are vaccinated, changing the immune landscape of the host population and the immune-mediated competition between these two human pathogens.
To examine the mechanisms used by B. parapertussis to evade B. pertussis vaccines-induced immunity, we showed that a B. pertussis whole cell vaccine (wP) had some effect, but a commercial acellular vaccine (aP) had no effect against B. parapertussis growth in mouse lungs. IFN-γ contributes to the protection against B. parapertussis by wP. O-antigen shielded B. parapertussis from the binding of vaccine-induced antibodies, interfered with opsonophagocytosis of B. parapertussis mediated by aP and wP-induced antibodies and blocked antibody-mediated clearance in vivo. wP conferred more protection against an isogenic B. parapertussis strain lacking O-antigen, indicating that O-antigen contributed to the evasion of wP-induced immunity. aP, however, failed to induce cross-protection against B. parapertussis with or without the hindrance of O-antigen. In B. pertussis vaccinated hosts, supplement of B. parapertussis-specific, but not B. pertussis-specific, antibodies conferred protection against B. parapertussis, indicating that the lack of proper antibody responses causes the failure of these vaccines against B. parapertussis. Together these results explain the clinical finding that B. parapertussis avoids clearance by the current vaccines, and provides a mechanistic understanding that will guide new approaches to overcoming this problem.
Materials and Methods
Bacterial strains and growth
B. pertussis strain 536, B. parapertussis strain CN2591 and its isogenic mutant lacking O-antigen, CN2591Δwbm, have been described previously , . For opsonization, attachment and phagocytosis experiments, these strains were transformed with plasmid pCW505 (kindly supplied by Dr. Alison Weiss, Cincinnati, Ohio) which induces cytoplasmic expression of GFP without affecting growth, or antigen expression . Bacteria were maintained on Bordet-Gengou agar (Difco) supplemented with 10% sheep's blood (Hema Resources) and 20 µg/mL streptomycin (Sigma-Aldrich). Liquid cultures were grown overnight in Stainer-Scholte broth at 37°C to mid-log phase , .
Peripheral blood polymorphonuclear leukocytes (PMNs) were isolated from heparinized venous blood using Ficoll-Histopaque (Sigma, St Louis, MO) gradient centrifugation. PMNs were harvested and the remaining erythrocytes were removed by hypotonic lysis. Cell viability was >99% as determined by Trypan Blue exclusion. Prior to functional assays, PMNs were washed twice with Dulbecco's modified Eagle medium (DMEM) (Hyclone) supplemented with 10% of fetal calf serum (FCS) (Hyclone), resuspended, and used immediately. All experiments were carried out with freshly isolated PMNs lacking FcγRI (CD64) expression, as monitored by FACS analysis using a fluorescence-activated cell sorter FACScan (Becton Dickinson, San Jose, CA) with anti-FcγRI mAb 22 .
GFP-expressing strains were opsonized by incubation at 37°C with 5% heat-inactivated wP-induced/naive or aP/adjuvant-induced serum samples for 30 min in a final volume of 50 µL. Serum opsonized bacteria were incubated with R-phycoerythrin (RPE)–labeled goat F(ab′)2 fragments of anti-mouse IgG (Southern Biotechnology, Birmingham, AL) for 30 min at 4°C. Opsonization of each Bordetella strain was determined by FACS analysis .
Attachment and phagocytosis
Attachment and phagocytosis of the Bordetella strains were evaluated as previously described with a few modifications . Briefly, serum opsonized GFP-expressing bacteria were incubated with PMNs at multiplicity of infection (MOI) of 30 for 20 min at 37°C to allow binding. After extensive washing to remove non-attached bacteria, an aliquot was maintained on ice to be used for bacterial attachment control. Another aliquot was further incubated for 1 h at 37°C to allow internalization. Phagocytosis was stopped by placing PMNs on ice. Cell surface bound bacteria in both aliquots (before and after 1 hour incubation at 37°C) were detected by incubation with RPE–labeled goat F(ab′)2 fragments of anti-mouse IgG at 4°C for 30 min. To avoid eventual nonspecific binding of antibodies, all incubations were done in the presence of 25% heat-inactivated human serum. After washing, samples were analyzed by flow cytometry. Ten thousand cells were analyzed per sample. Green fluorescence intensity associated with PMNs maintained at 37°C for 20 min has previously been shown to represent bacterial attachment . Phagocytosis was calculated from the drop in mean red fluorescence intensity of green-positive cells after incubation for additional1h at 37°C as described .
C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor) and bred in our Bordetella-free, specific pathogen-free breeding rooms at The Pennsylvania State University. 4–6 week old mice were sedated with 5% isoflurane (Abbott Laboratory) in oxygen and vaccinated by intraperitoneally (i.p.) injection of 1×108 CFU of heat-inactivated bacteria in 1 mL of phosphate balanced saline (PBS, Omnipur) (wP), 1/5 human dose of Adacel (Sanofi Pastuer) (0.5 µg PT, 1 µg FHA, 0.6 µg pertactin, 5 µg fimbriae 2 and 3 per mouse) with Imject Alum (Thermo Scientific) (aP) or only Imject Alum in 200 µL PBS on day 14 and 28 prior to challenge . For challenge, mice were sedated and inoculated by pipetting 50 µL PBS containing 5×105 CFU of the indicated bacteria onto the external nares . This method reliably distributes the bacteria throughout the respiratory tract . For adoptive transfer of immune serum, mice were vaccinated with the indicated bacteria on day 0 and 14 and sera were collected on day 28 or sera were collected from naïve animals. 200 µL of sera were i.p. injected at the time of inoculation , . For quantification of bacteria numbers, mice were sacrificed via CO2 inhalation and the lung, trachea, and nasal cavity were excised. Tissues were homogenized in PBS, serial diluted and plated onto Bordet-Gengou agar plates with 20 µg/mL streptomycin, and colonies were counted after incubation at 37°C for 3–5 days . Gamma interferon (IFN-γ) was depleted by i.p. injections of 5 mg of the antibody from hybridoma XMG1.2 one day prior to challenge . The lower limit of detection was 10 CFU. For all experiments, protocols were reviewed and approved by the Pennsylvania State University IACUC and all animal were handled in accordance with institutional guidelines.
Spleens were excised from groups of 3–4 C57BL/6 mice after vaccination. Splenocytes were isolated as previously described , . In brief, spleens were homogenized and red blood cells were lysed with 0.84% ammonium chloride. 2×106 cells were re-suspended in DMEM supplemented with 10% FCS, 1 mM sodium pyruvate (HyClone), and 100 µg/mL penicillin and streptocycin (HyClone) and placed into each well of a 96-well tissue culture plate. Splenocytes were stimulated with either media alone or media containing 107 CFU (MOI of 5) of the indicated bacteria that had been heat-killed , . After three days, the supernatants were collected and analyzed for IFN-γ and interleukin-10 (IL-10) production via Enzyme-linked immunosorbent assays (ELISA) as per the manufacturers' instructions (R&D Systems).
Antibody titers were determined as previously described , , . Briefly, heat-inactivated or exponential phase live bacteria were diluted to 5×107 CFU/mL in a 1∶1 mix of 0.2 M sodium carbonate and 0.2 M sodium bicarbonate buffers. These antigens were coated onto 96-well plates, incubated for 2 h at 37°C in a humidified chamber, washed and blocked. A1∶50 or 1∶10 dilution of wP-induced/naive or aP/adjuvant-induced serum samples from an individual mouse was added to the first well of each row and serially diluted 1∶2 across the plates. Plates were incubated for 2 h at 37°C, washed and probed with 1∶4000 dilution of goat anti-mouse Ig horseradish peroxidase (HRP)-conjugated antibodies (Southern Biotech) for 1 h and visualized with 2,2′-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt in phosphate-citrate buffer with hydrogen peroxide at an absorbance of 405 nm. Titers were determined via the endpoint method based on optimal density of identically treated wells probed with naïve or adjuvant-induced sera.
Western blot analysis
Lysates containing 5×105 CFU of indicated heat-killed bacteria were run on 7% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels in denaturing conditions. Polyvinylidene Fluoride (PVDF) membranes (Millipore) were probed overnight with either naïve serum or serum from vaccinated mice at a 1∶10 or 1∶100 dilution for aP and wP-induced serum respectively. 1∶10,000 dilution of goat anti-mouse Ig HRP-conjugated antibodies (Southern Biotech) was used as the detector antibody , . The membrane was visualized with ECL Western Blotting Detection Reagent (Pierce Biotechnology).
The means +/− standard error (error bars) were determined for all appropriate data. Two-tailed, unpaired Student's T-tests were used to determine statistical significance between groups. Results were also analyzed by ANOVA and Tukey simultaneous test in Minitab with similar significance. All experiments were performed at least twice with similar results.
B. parapertussis O-antigen contributes to the evasion of wP–induced immunity
To examine whether wP is cross-protective against B. parapertussis and whether O-antigen interferes with its cross-protection, naïve or wP vaccinated C57BL/6 mice were challenged with 5×105 CFU of B. pertussis, B. parapertussis or an isogenic B. parapertussis strain lacking O-antigen (BppΔwbm). In comparison to naïve mice, wP treatment reduced B. pertussis numbers by 91.9%, 97.8% and >99.9% in the nasal cavity, trachea and lungs by day 3 post challenge; naïve mice having about 7000 fold more bacteria in the lungs than vaccinated mice (Figure 1A). wP vaccination reduced B. parapertussis loads by 76.6%, 83.0% and 97.6% in the nasal cavity, trachea and lung; naïve mice having about 40 fold more bacteria in the lungs than vaccinated mice (Figure 1A). These results are consistent with multiple clinical studies showing whole cell vaccines confer good protection against B. pertussis but relatively little protection against B. parapertussis , , . Interestingly, compared to naïve mice, wP reduced numbers of an O-antigen deficient B. parapertussis strain by 89.4%, 99% and >99.9% in the nasal cavity, trachea and lung; naïve mice having around 2000 fold more bacteria in the lungs than vaccinated mice (Figure 1A). The fold protection (reduction of bacterial number in each individual vaccinated mouse compared to mean number of bacteria in naive mice on day 3 post-challenge) of wP against O-antigen deficient B. parapertussis was significantly higher than against wild-type B. parapertussis in both trachea and lung (lung: P = 0.0006, trachea: P = 0.018), indicating that wP is more efficacious against O-antigen deficient B. parapertussis.
Groups of four naïve (black) or wP vaccinated (white) C57BL/6 mice were challenged with the indicated bacteria. (A) The number of CFUs recovered from the respiratory tract on day 3 post-challenge is expressed as the Log10 mean ± the standard error. Decreases in Log10CFU in vaccinated mice compared to naïve mice on day 3 post-challenge are indicated underneath the x axes. (B) The change in CFU number over the first 3 days after challenge is expressed as change in Log10 mean ± the standard error. * indicates P≤0.05. ** indicates P≤0.01. The limit of detection is indicated as the lower limit of the y axes.
To understand how vaccination affects the infection, it is important to examine these effects in the context of the dynamic infectious process. B. pertussis and B. parapertussis increased in numbers throughout the respiratory tract of naïve mice over 3 days, reflecting effective colonization and bacterial growth (Figure 1B). O-antigen deficient B. parapertussis grew in the nasal cavity and trachea but not in the lungs of naïve mice due to its increased susceptibility to complement  (Figure 1B). wP decreased the numbers of B. pertussis in all respiratory organs over 3 days, resulting in a net decline in numbers, particularly in the lower respiratory tract (LRT). Vaccination did not decrease B. parapertussis numbers as efficiently in the lung and B. parapertussis actually grew in numbers in the trachea and nasal cavity, reflecting successful colonization and expansion despite vaccination (Figure 1B). Interestingly, wP vaccination decreased O-antigen deficient B. parapertussis numbers as efficiently as it did B. pertussis numbers in the trachea and lung (Figure 1B). Together these results are consistent with clinical studies showing that wP vaccination confers relatively little protection against B. parapertussis and show that O-antigen is required for B. parapertussis to avoid efficient wP vaccine-induced immunity.
Many developed countries have switched to acellular vaccines, although these provide even less protection against B. parapertussis , , . We therefore determined if the O-antigen of B. parapertussis contributes to the evasion of aP-induced immunity. While aP reduced B. pertussis colonization in both lung and trachea of vaccinated mice by 99.7% and 96.8% compared to the mice given just adjuvant, aP had no effects on either B. parapertussis or O-antigen deficient B. parapertussis colonization (Figure 2). These data indicate that aP does not induce protective immunity against B. parapertussis.
Groups of four C57BL/6 mice were vaccinated with adjuvant only (black) or aP (white), challenged with the indicated bacteria and sacrificed on day 3 post-challenge. The numbers of CFUs recovered from the respiratory tract are expressed as the Log10 mean ± the standard error. ** indicates P≤0.01. The limit of detection is indicated as the lower limit of the y axes.
wP induces T cells that cross react with B. parapertussis
To investigate why aP is less effective than wP against B. parapertussis and why wP confers different levels of protection against B. pertussis, O-antigen deficient and wild-type B. parapertussis, we compared their induction of T cell responses known to be important for control and clearance of B. parapertussis . Splenocytes from mice that were naïve, vaccinated with wP, aP or adjuvant were stimulated with heat-killed B. pertussis or wild-type or O-antigen deficient B. parapertussis. After 3 days, IFN-γ and IL-10 production, representative of TH1 and TH2 responses, was measured. aP vaccination did not affect IFN-γ or IL-10 levels, which were similar to those induced by naïve and adjuvant-treated controls (Figure 3). In contrast, splenocytes from wP-vaccinated mice responded similarly to heat-killed B. parapertussis or B. pertussis, producing significantly higher IFN-γ and IL-10 than splenocytes from naïve or adjuvant-treated mice (Figure 3). IFN-γ and IL-10 production was abolished in TCRβ/δ−/− mice (data not shown), indicating that vaccine-induced IFN-γ and IL-10 production is dependent on T cells. These data indicate that the T-cell response to wP is cross-reactive to B. parapertussis and that O-antigen did not affect the T cell response.
Splenocytes from groups of four naïve C57BL/6 mice or mice vaccinated with the indicated vaccine were stimulated with media only (vertically hatched), heat-killed B. pertussis (black), B. parapertussis (white) or O-antigen deficient B. parapertussis (horizontally hatched) for 3 days. The concentration of IFN-γ and IL-10 in the supernatant is expressed as the mean ± the standard error. ND indicates none detected.
IFN-γ contributes to wP–induced protection against B. parapertussis
In the vaccination studies above (Figure 1, Figure 2), protection against B. parapertussis correlates with the high IFN-γ responses of wP but not aP vaccinated animals (Figure 3). IFN-γ has been shown to contribute to leukocyte recruitment and the reduction of bacterial numbers during B. parapertussis infection (D.N. Wolfe, A.T. Karanikas, S.E. Hester, M.J. Kennett, E.T. Harvill, submitted for publication). To determine how the cross-reactive IFN-γ response after wP vaccination might contribute to its protection against B. parapertussis, naïve or wP vaccinated mice were left untreated or depleted of IFN-γ, challenged with B. pertussis or B. parapertussis and sacrificed 3 days later for bacterial enumeration. Vaccination or IFN-γ depletion had no effects on colonization of the nasal cavity (Figure 4). However, B. pertussis numbers were reduced by >99.9% and >99.5% in the lung and trachea of vaccinated mice compared to naïve mice regardless of the presence or absence of IFN-γ (Figure 4). Although wP reduced B. parapertussis numbers in the lung and trachea by about 98.6% and 99.6%, this effect was abolished in mice given IFN-γ neutralizing antibodies (Figure 4), indicating that IFN-γ contributes to the protection conferred by wP against B. parapertussis.
Groups of four naïve (black and horizontally hatched) or wP vaccinated (white and vertically hatched) C57BL/6 mice were untreated (−) (black and white) or i.p. injected with (+) (horizontally and vertically hatched) anti-IFN-γ antibody, challenged with B. parapertussis and sacrificed 3 days post-challenge. The number of CFUs throughout the respiratory tract is expressed as the Log10 mean ± the standard error. * indicates P≤0.05. ** indicates P≤0.01. The limit of detection is indicated as the lower limit of the y axes.
Serum antibody responses to aP and wP are cross-reactive to denatured but not live B. parapertussis
We have previously shown that antibodies are required for anamnestic immunity to B. parapertussis . To determine whether B. pertussis vaccines induce antibodies that recognize and/or protect against B. parapertussis, we first tested whether antibody responses are cross-reactive between strains and if O-antigen affects the responsiveness of antibodies. In a western blot, whole cell extracts of B. pertussis, wild-type and O-antigen deficient B. parapertussis were probed with serum antibodies from aP, adjuvant only, wP vaccinated or naïve mice. Compared to the control, aP vaccination induced serum antibodies that recognized distinct antigens present in all three bacteria, although the size and intensity of bands appeared to differ between B. pertussis and B. parapertussis. While wP-induced serum antibodies recognized four major bands in denatured B. parapertussis, they recognize more antigens in B. pertussis, especially those of high molecular weights (Figure 5A).
(A) Western blots were performed on lysates of indicated bacteria probed with serum antibodies collected from mice that were vaccinated with aP, adjuvant only (Adj) or wP. (B) Heat-inactivated or (C) live B. pertussis (black), B. parapertussis (white) or O-antigen deficient B. parapertussis (hatched) were coated on ELISA plate. Serum antibody titer of mice vaccinated with aP or wP is expressed as mean of the end point titers of four independent samples ± the standard error. ** indicates P≤0.01. The dashed line indicates the limit of detection.
To quantify the cross-reactivity of antibodies, we determined the titers of aP or wP-induced serum antibodies by ELISA using heat-inactivated bacteria as antigens. wP-induced sera had much higher titers than aP-induced sera (Figure 5B). For both aP and wP-induced serum antibodies, B. pertussis-specific antibody titers were much higher than B. parapertussis-specific antibody titers regardless of the presence or absence of O-antigen (Figure 5B). Since heat killing releases many antigens that are not exposed on the surface of live bacteria, similar experiments were performed with live bacteria as antigens. Interestingly, both wP and aP-induced serum antibodies bound to live B. parapertussis more efficiently in the absence of O-antigen (Figure 5C). These data suggest that O-antigen interferes with the binding of B. pertussis vaccine-induced antibodies to live B. parapertussis.
O-antigen inhibits aP– and wP–induced, antibody-mediated opsonization and subsequent attachment to, and phagocytosis by, PMNs
To determine whether O-antigen interferes with key functions of antibodies, we assessed its effects on opsonization and subsequent attachment to and phagocytosis by PMNs mediated by aP or wP induced antibodies. Consistent with the ELISA results (Figure 5C), B. pertussis was efficiently opsonized by both aP and wP-induced serum antibodies (Figure 6A, 6B, and 6D). Although B. parapertussis was efficiently opsonized by whole cell B. parapertussis (wPP)-induced serum antibodies (Figure 6C and 6D), aP or wP-induced antibodies failed to opsonize this bacterium (Figure 6A, 6B, and 6D). In contrast, O-antigen deficient B. parapertussis was efficiently opsonized by aP or wP-induced antibodies (Figure 6A, 6B, and 6D), indicating that O-antigen hinders the opsonization of B. parapertussis by both aP and wP-induced serum antibodies.
Representative histograms show flow cytometric analysis of indicated bacteria opsonized with naïve serum (white) or (A) aP, (B) wP, (C) wPP-induced serum (grey) and stained with RPE-labeled goat F(ab)2 fragments of anti-mouse IgG. (D) Mean red-fluorescence of B. pertussis (black), B. parapertussis (white), O-antigen deficient B. parapertussis (hatched) opsonized with indicated serum from four individual mice ± the standard error is shown. AU indicates arbitrary units. ** indicates P≤0.01.
To examine if O-antigen blocking of opsonization results in inhibitory effects on attachment of B. parapertussis to phagocytes, bacteria opsonized with vaccine-induced antibodies were further incubated with polymorphonuclear leukocytes (PMN) for 20 mins and cell surface bound bacteria numbers were identified by flow cytometry. aP or wP-induced-antibody-opsonized B. pertussis attached to PMNs efficiently (Figure 7A, 7B, and 7D). B. parapertussis attached to PMN after opsonization with wPP-induced serum antibodies (Figure 7C and 7D), but neither aP nor wP-induced antibodies mediated attachment of this bacterium to PMNs (Figure 7A, 7B, and 7D). B. parapertussis lacking O-antigen, opsonized with aP or wP-induced antibodies, efficiently attached to phagocytes (Figure 7A, 7B, and 7D), indicating that O-antigen also inhibits this process.
Naïve serum (white) or (A) aP, (B) wP, (C) wPP-induced serum (grey)-opsonized GFP-expressing bacteria were incubated with freshly isolated human peripheral blood PMNs. Representative histograms of flow cytometry analysis of these cells are shown. (D) Mean green fluorescence associated with PMNs incubated with GFP-expressing B. pertussis (black), B. parapertussis (white) or O-antigen deficient B. parapertussis (hatched) opsonized with four independent indicated serum ± the standard error is shown. AU indicates arbitrary units. ** indicates P≤0.01.
To determine if O-antigen interferes with aP or wP-induced antibodies ability to mediate phagocytosis of B. parapertussis by PMNs, an aliquot of cells from the attachment experiment was incubated for one extra hour and phagocytosis was measured. No significant internalization of naïve serum-opsonized bacteria was observed. B. pertussis opsonized with aP or wP-induced antibodies was efficiently phagocytosed, but similarly treated B. parapertussis was not (Figure 8). In contrast, wPP-induced antibody-opsonized B. parapertussis was efficiently internalized by PMNs (Figure 8). B. parapertussis lacking O-antigen opsonized by aP or wP-induced antibodies was efficiently phagocytosed by PMNs. Together these results indicate that O-antigen protects B. parapertussis from aP or wP-induced serum antibody mediated opsonization, attachment to phagocytes and subsequent internalization by these cells.
Freshly isolated human peripheral blood PMNs were incubated for 20 min or 1 h and 20 min with GFP-expressing B. pertussis (black), B. parapertussis (white), or O-antigen deficient B. parapertussis (hatched), that are opsonized with serum from aP, wP, wPP-vaccinated or naïve mice. The cell surface bound bacteria were detected by incubation with RPE-labeled goat F(ab')2 fragments of anti-mouse IgG. Mean phagocytosis calculated from the decrease in red-fluorescence of green-positive cells incubated for 1 h and 20 min compared to that incubated for 20 min of experiments done with 4 independent serum samples ± the standard error was shown. AU indicates arbitrary units. ** indicates P≤0.01.
O-antigen blocks antibody-mediated clearance of B. parapertussis from mouse lungs
Since O-antigen interferes with the binding of B. pertussis vaccine-induced antibodies to live B. parapertussis and phagocytosis dependent on these antibodies in vitro, we tested if O-antigen inhibits antibody-mediated clearance in vivo. Serum from naïve (NS), wP- or wPP-vaccinated mice were transferred to naïve animals. Bacterial loads in the lungs were determined on day 14 post B. parapertussis challenge since antibodies have no effect until B. parapertussis specific T cell responses are generated around day 14 ,  (D.N. Wolfe unpublished data). Serum from wPP vaccinated animals significantly lowered numbers of both wild-type and O-antigen deficient B. parapertussis compared to naïve serum treated animals and modestly reduced B. pertussis numbers (Figure 9). This indicates that although lower level of phagocytosis of O-antigen deficient B. parapertussis mediated by wPP-induced serum antibodies were observed compared to wild-type strain (Figure 8), this low level of phagocytosis and/or other biological activities of passively transferred antibodies might be sufficient to reduce O-antigen deficient strain in vivo (Figure 9). wP-induced serum completely cleared B. pertussis from the lung by day 14 post-challenge but did not reduce B. parapertussis numbers. These serum antibodies did, however, reduce the numbers of O-antigen deficient B. parapertussis by more than 90% (Figure 9), indicating that O-antigen prevents the wP-induced serum antibody mediated reduction of B. parapertussis numbers in vivo.
Groups of four C57BL/6 mice were adoptively transferred naïve serum (black), wP-induced serum (white) or wPP-induced serum (hatched) at the time of bacterial challenge and dissected 14 days later. The number of CFUs recovered from lung is expressed as the Log10 mean ± the standard error. * indicates P≤0.05 and ** indicates P≤0.01 compared to mice given naïve serum. The limit of detection is indicated as the lower limit of the y axes. ND indicates undetectable bacterial number.
B. parapertussis–specific antibodies augment B. pertussis vaccine-induced protective immunity against B. parapertussis
We have previously shown that both antibodies and T cells are required for anamnestic protective immunity against B. parapertussis . Although wP vaccination induced T cell responses that were cross-reactive (Figure 4) and antibodies that bound antigens from heat-killed B. parapertussis (Figure 5B), O-antigen decreased the binding of these antibodies to live B. parapertussis (Figure 5), the opsonophagocytosis mediated by these antibodies in vitro (Figure 6, Figure 7, Figure 8) and their antibody-mediated clearance in vivo (Figure 9). Based on these observations, we hypothesized that wP induces sufficient T cell response but the antibody response is not sufficient to clear B. parapertussis because O-antigen protects B. parapertussis from wP-induced antibodies. If this were the case, then adding antibodies that bind live B. parapertussis should render wP induced immunity sufficient to rapidly clear B. parapertussis. To test this, mice were vaccinated with aP (Figure 10A) or wP (Figure 10B), these vaccinated mice were left untreated or given naïve, wP or wPP-induced serum antibodies at the time of B. parapertussis challenge and sacrificed three days after challenge. To compare the protective immunity to that generated by B. parapertussis, a group of mice were vaccinated with wPP and adoptively transferred with wPP-induced antibodies. Less than 100 CFUs of B. parapertussis were recovered in the LRT of this group of mice by day 3 post-challenge (Figure 10B). The very high titers of this wPP-induced serum antibodies alone had modest effect on reducing B. parapertussis numbers (Figure 10B), consistent with prior results with convalescent serum , . In both aP and wP vaccinated mice, naïve sera had no effect, indicating that components in the serum other than those induced by vaccination do not affect bacteria numbers. Transfer of wP-induced sera had no effect on B. parapertussis colonization throughout the respiratory tract. However, B. parapertussis numbers were significantly lower in the LRT of both aP and wP vaccinated animals given wPP-induced sera than in those given naïve sera (Figure 10). These data suggest that the addition of B. parapertussis specific antibodies is sufficient to render wP and aP effective against B. parapertussis.
Groups of four C57BL/6 mice were (B) left untreated (−) or vaccinated with (A) aP, (B) wPP or wP. Mice lacking a transfer of antibodies (−) or given naïve serum (NS), wP-induced serum (wP IS) or wPP-induced serum (wPP IS) were challenged with B. parapertussis. Mice were sacrificed three days post-challenge and the number of CFUs recovered from the respiratory tract is expressed as the Log10 mean ± the standard error. ** indicates P≤0.01. The limit of detection is indicated as the lower limit of the y axes.
The increasing incidence of whooping cough in highly vaccinated developed countries includes an unknown proportion of B. parapertussis infections, . Multiple clinical and experimental studies have shown that current whooping cough vaccines have little efficacy against this bacterium –, but have not revealed why. In this study, we determined that O-antigen shields vaccine-induced antibodies from binding to B. parapertussis and prevents antibody-mediated opsonophagocytosis in vitro and antibody-mediated clearance in vivo. Although O-antigen requires a large multigenic wbm locus to produce and B. pertussis is still successful in the human population without this surface antigen , it is retained in B. parapertussis . Apart from its role in inhibiting complement deposition and complement-mediated killing , our study suggests that O-antigen, by decreasing B. pertussis-vaccine-induced antibody binding, may confer a selective advantage to B. parapertussis in human populations in which there is high prevalence of detectable immunity to B. pertussis.
It is interesting that wP, but not aP, induced IFN-γ, which contributed to protection against B. parapertussis but not B. pertussis (Figure 4). IFN-γ plays a role in the recruitment and activation of phagocytic cells , . In B. parapertussis infected mice, the peak of neutrophil numbers in the lung on day 7 and subsequent control of B. parapertussis numbers are dependent on IFN-γ (D.N. Wolfe, A.T. Karanikas, S.E. Hester, M.J. Kennett, E.T. Harvill, submitted for publication). B. pertussis challenged IFN-γ−/− mice, however, have an indistinguishable course of infection in the respiratory tract and recruit similar numbers of leukocytes to the site of infection as compared to wild-type mice  (Wolfe unpublished data), indicating that IFN-γ is not required for B. pertussis clearance and leukocyte recruitment. In vaccinated IFN-γR−/− mice, no impaired reduction of B. pertussis numbers is observed during the first week after challenge, although a rebound of bacteria number was observed on day 10 . This is consistent with our observation that IFN-γ is not required for vaccine-mediated control of B. pertussis numbers on day 3 post-challenge (Figure 4).
Consistent with multiple clinical and experimental studies, we found that while wP confers some level of protection against B. parapertussis, aP does not , . The decrease of pertussis acellular vaccines efficacy against B. parapertussis compared to whole cell vaccines has been suggested to be attributable to the failure of antibodies induced by pertussis acellular vaccines to block the adherence of B. parapertussis to epithelial cells  or the immune suppressive effects of the FHA included in those vaccines . Among the antigens included in the aP, only fimbriae, but not FHA and pertactin, was shown to confer cross-protection against B. parapertussis in a mouse model , . wP contains more antigens than aP, among which there may be cross-protective antigens. Alternatively, the differences in Th1/Th2 skewing of wP and aP may affect vaccine efficacy. wP induces a relatively balanced Th1/Th2 response whereas aP induces a Th2-type response . Our data showed that wP, but not aP, induced high splenic IFN-γ production and wP was no longer protective against B. parapertussis when IFN-γ was depleted, suggesting that IFN-γ contributes to the protection conferred by wP (Figure 3, Figure 4). These data are therefore consistent with the idea that inducing a Th1 response enhances immunity against B. parapertussis. The different Th1/Th2 skewing, quantity and quality of cross-reactive antibodies and possible immune suppression factors in aP may also explain why aP vaccination was not sufficient to induce protection against B. parapertussis even without the hindrance by O-antigen.
Our data reveal an interesting paradox. wP-mediated clearance of B. parapertussis by day 3 requires IFN-γ, which aP does not induce (Figure 3, Figure 4). Yet when wPP-induced antibodies, which had limited effect in naïve animals in the first week of infection (Figure 10B) , were given to aP-vaccinated animals, B. parapertussis was effectively cleared from mouse lungs within 3 days (Figure 10A). IFN-γ appears to contribute to the protection conferred by wP, but aP-vaccination contributes to rapid clearance despite the lack of detectable IFN-γ induction in our splenocyte re-stimulation assay (Figure 3). It is possible that some low level of IFN-γ was induced by aP vaccination, which we failed to detect, or some other cross-reactive protective T cell cytokine responses aid in the rapid clearance mediated by B. parapertussis-specific antibodies in aP-vaccinated animals.
Although it is not clear how much B. parapertussis contributes to the resurgence of whooping cough, the low efficacy of current vaccines against this bacterium might confer a selective advantage to B. parapertussis, relative to B. pertussis. Moreover, the lower protection against B. parapertussis conferred by acellular vaccines than whole cell vaccine could affect the relative prevalence, a possibility of greater significance since the recent switch from whole cell to acellular vaccines and the even more recent introduction of acellular vaccines, including the one used here, for adolescents and adults , , , . Considering adults to be a possible reservoir for transmission to infants , , the lack of cross-protection of Adacel, determined in this study, may open a niche for B. parapertussis not only in adolescents/adults but also in infants. This study shows that B. parapertussis evades B. pertussis vaccine induced immunity by blocking cross-reactive antibodies binding via O-antigen. Our current data provide strong evidence that including more B. pertussis proteins that induce antibodies that recognize orthologs in B. parapertusis is unlikely to improve vaccines so that they protect against B. parapertussis. Since our study indicates that supplementing wP or aP with B. parapertussis-specific antibodies rendered them effective against B. parapertussis (Figure 10), addition of protective antigens of B. parapertussis to the vaccine may substantially improve its efficacy against this pathogen.
We would like to thank Dr. Daniel N. Wolfe and Dr. Anne M. Buboltz for discussion and critical review of the manuscript.
Conceived and designed the experiments: XZ MER ETH. Performed the experiments: XZ MER. Analyzed the data: XZ MER. Wrote the paper: XZ MER ETH.
- 1. Mattoo S, Cherry JD (2005) Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18: 326–382.
- 2. Cherry JD, Brunell PA, Golden GS, Karson DT (1988) Report of the task force on pertussis and pertussis immunization-1988. Pediatrics 81:
- 3. (2002) From the Centers for Disease Control and Prevention. Pertussis–United States, 1997-2000. JAMA 287: 977–979.
- 4. Celentano LP , M M, Paramatti D, Salmaso S, Tozzi AEEUVAC-NET Group (2005) Resurgence of pertussis in Europe. Pediatr Infect Dis J 24: 761–765.
- 5. de Melker HE , V F, Schellekens JF, Teunis PF, Kretzschmar M (2006) The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53: 106–113.
- 6. Hoppe JE (1999) Update on respiratory infection caused by Bordetella parapertussis. Pediatr Infect Dis J 18: 375–381.
- 7. Parkhill J, et al. (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 35: 32–40.
- 8. Diavatopoulos DA , C C, Schouls LM, Brinig MM, Relman DA, Mooi FR (2005) Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 1: e45.
- 9. van den Akker WM (1998) Lipopolysaccharide expression within the genus Bordetella: influence of temperature and phase variation. Microbiology 144: 1527–1535.
- 10. Preston A, Allen AG, Cadisch J, Thomas R, Stevens K, et al. (1999) Genetic basis for lipopolysaccharide O-antigen biosynthesis in bordetellae. Infect Immun 67: 3763–3767.
- 11. Marchitto KS, Smith SG, Locht C, Keith JM (1987) Nucleotide sequence homology to pertussis toxin gene in Bordetella bronchiseptica and Bordetella parapertussis. Infect Immun 55: 497–501.
- 12. Arico B, Rappuoli R (1987) Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol 169: 2847–2853.
- 13. Watanabe M , N M (2004) Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Ther 2: 447–454.
- 14. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J (1998) Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280: 635–637.
- 15. Mastrantonio P, Stefanelli P, Giulano M, Herrera Rojas Y, Ciofi degli Atti M, Anemona A, Tozzi AE (1998) Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol 36: 999–1002.
- 16. Liese JG , R C, Stojanov S, Belohradsky BH, Munich Vaccine Study Group (2003) Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines. Arch Dis Child 88: 684–687.
- 17. Heininger U , S K, Christenson P, Cherry JD (1998) Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clin Infect Dis 28: 602–604.
- 18. David S, van Furth R, Mooi FR (2004) Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine 22: 1892–1898.
- 19. Wolfe DN, Goebel EM, Bjornstad ON, Restif O, Harvill ET (2007) The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun 75: 4972–4979.
- 20. Stibitz S, Yang MS (1991) Subcellular localization and immunological detection of proteins encoded by the vir locus of Bordetella pertussis. J Bacteriol 173: 4288–4296.
- 21. Weingart CL, Broitman-Maduro G, Dean G, Newman S, Peppler M, et al. (1999) Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 67: 4264–4267.
- 22. von Koenig CH, Tacken A, Finger H (1988) Use of supplemented Stainer-Scholte broth for the isolation of Bordetella pertussis from clinical material. J Clin Microbiol 26: 2558–2560.
- 23. Stainer DW, Scholte MJ (1970) A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol 63: 211–220.
- 24. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, et al. (1991) Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 78: 885–889.
- 25. Rodriguez ME, Van der Pol WL, Van de Winkel JG (2001) Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. J Immunol Methods 252: 33–44.
- 26. Rodriguez ME, Hellwig SM, Hozbor DF, Leusen J, van der Pol WL, et al. (2001) Fc receptor-mediated immunity against Bordetella pertussis. J Immunol 167: 6545–6551.
- 27. Gopinathan L, Kirimanjeswara GS, Wolfe DN, Kelley ML, Harvill ET (2007) Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect 9: 442–448.
- 28. Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET (2005) Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 115: 3594–3601.
- 29. Harvill ET, Preston A, Cotter PA, Allen AG, Maskell DJ, et al. (2000) Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect Immun 68: 6720–6728.
- 30. Kirimanjeswara GS, Mann PB, Harvill ET (2003) Role of antibodies in immunity to Bordetella infections. Infect Immun 71: 1719–1724.
- 31. Pishko EJ, Kirimanjeswara GS, Pilione MR, Gopinathan L, Kennett MJ, et al. (2004) Antibody-mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3. Eur J Immunol 34: 184–193.
- 32. Parent MA, Wilhelm LB, Kummer LW, Szaba FM, Mullarky IK, et al. (2006) Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun 74: 3381–3386.
- 33. Pilione MR , H E (2006) The Bordetella bronchiseptica type III secretion system inhibits gamma interferon production that is required for efficient antibody-mediated bacterial clearance. Infect Immun 74: 1043–1049.
- 34. Wolfe DN , K G, Harvill ET (2005) Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity. Infect Immun 73: 6508–6513.
- 35. Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, et al. (1997) The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 4: 113–116.
- 36. Wolfe DN, Kirimanjeswara GS, Goebel EM, Harvill ET (2007) Comparative role of immunoglobulin A in protective immunity against the Bordetellae. Infect Immun 75: 4416–4422.
- 37. Willems RJ, Kamerbeek J, Geuijen CA, Top J, Gielen H, Gaastra W, Mooi FR (1998) The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. Vaccine 16: 410–416.
- 38. Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET (2008) O antigen protects Bordetella parapertussis from complement. Infect Immun 76: 1774–1780.
- 39. Wolfe DN, Buboltz AM, Harvill ET (2009) Inefficient Toll-like receptor-4 stimulation enables Bordetella parapertussis to avoid host immunity. PLoS ONE 4: e4280.
- 40. Burns V, Pishko EJ, Preston A, Maskell DJ, Harvill ET (2003) Role of Bordetella O-antigen in respiratory tract infection. Infect Immun 71: 86–94.
- 41. Sun K, Salmon SL, Lotz SA, Metzger DW (2007) Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun 75: 1196–1202.
- 42. Ellis TN, Beaman BL (2004) Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology 112: 2–12.
- 43. Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH (1997) Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med 186: 1843–1851.
- 44. Mills KH, Brady M, Ryan E, Mahon BP (1998) A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity. Dev Biol Stand 95: 31–41.
- 45. van den Berg BM, Beekhuizen H, Mooi FR, van Furth R (1999) Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells. Infect Immun 67: 1050–1055.
- 46. McGuirk P, McCann C, Mills KH (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195: 221–231.
- 47. Khelef N, Danve B, Quentin-Millet MJ, Guiso N (1993) Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immun 61: 486–490.
- 48. Mills KH (2001) Immunity to Bordetella pertussis. Microbes Infect 3: 655–677.
- 49. CDC (2006) Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine. MMWR 55: 1–33.
- 50. (2006) Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 117: 965–978.
- 51. Nelson JD (1978) The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child 132: 371–373.
- 52. Wirsing von Konig CH, Postels-Multani S, Bock HL, Schmitt HJ (1995) Pertussis in adults: frequency of transmission after household exposure. Lancet 346: 1326–1329.